Our results indicate that these proteins, such as CPN, C3, AGT and ACT-1, which showed significant changes after the standard therapy for CHF, can be used for disease monitoring and may relate to beneficial effects of the medication. The gene discussed is AGT; the disease is congestive heart failure.